INVESTOR ALERT: Lundin Law PC Announces Investigation of Clovis Oncology, Inc. and Urges Investors to Contact the Firm
December 01 2015 - 9:40PM
Business Wire
Lundin Law PC announces it is investigating claims against
Clovis Oncology, Inc. (“Clovis” or the “Company”) (NASDAQ: CLVS)
concerning possible violations of federal securities laws. The
investigation is related to allegations that certain statements
issued by Clovis were false and misleading concerning the Company’s
financial performance.
To participate in this class action lawsuit, please contact
Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via
e-mail at brian@lundinlawpc.com.
No class has been certified in the above action. Until a class
is certified, you are not considered represented by an attorney.
You may also choose to do nothing and be an absent class
member.
The investigation concerns whether the Company violated Sections
10(b) and 20(a) of the Securities Exchange Act of 1934.
Specifically, the investigation will focus on the Company’s
November 16, 2015, announcement that potential approval of its lung
cancer treatment rociletinib will likely be delayed.
Lundin Law PC was created by Brian Lundin, a securities
litigator based in Los Angeles.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151201006941/en/
Lundin Law PCBrian Lundin, Esq.Telephone: 888-713-1033Facsimile:
888-713-1125brian@lundinlaw.com
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Sep 2023 to Sep 2024